Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joshua Halpern

Plastic and Reconstructive Surgery Tampa, FL Medical Doctor

NPI 1366657447 CMS profile 914414

4214 N Habana Ave, Tampa, FL 33607

Open in the dashboard

General payments

$7,143

77 records reported · program years 2019–2025

Research payments

$4,091

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$41,558 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Joshua Halpern of Tampa, FL is reported in the CMS Open Payments database as having received $7,143 across 77 general payments and $4,091 in research payments paid to them. Separately, studies naming them as principal investigator received $41,558 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 84th percentile of Plastic and Reconstructive Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $499 8
2024 General $726 8
2023 General $1,322 12
2022 General $377 10
2022 Research $1,750 1
2021 General $561 10
2021 Research $2,080 1
2020 General $194 8
2019 General $3,464 21
2019 Research $261 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joshua Halpern
  • Plastic and Reconstructive Surgery median
  • Middle half of Plastic and Reconstructive Surgery
  • National median

In program year 2025, general payments to Joshua Halpern were reported at $499. Among 2,070 Plastic and Reconstructive Surgery profiles paid that year, the median was $442 and the middle half received between $150 and $1,242.

Show as a table
Year Joshua Halpern Plastic and Reconstructive Surgery median Middle half National median
2019 $3,464 $335 $121–$1,264 $163
2020 $194 $162 $57–$417 $114
2021 $561 $245 $89–$735 $132
2022 $377 $325 $120–$932 $149
2023 $1,322 $343 $129–$999 $160
2024 $726 $390 $141–$1,085 $164
2025 $499 $442 $150–$1,242 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Apyx Medical Corporation $2,378 9 payments
  2. Mentor Worldwide LLC $1,844 31 payments
  3. Merz North America, Inc. $1,014 18 payments
  4. Sientra, Inc. $551 4 payments
  5. TELA Bio, Inc. $337 2 payments
  6. Integra LifeSciences Corporation $230 2 payments
  7. Allergan Inc. $187 4 payments
  8. Coloplast Corp $143 1 payment
  9. AbbVie, Inc. $134 1 payment
  10. PolyNovo North America LLC $125 1 payment
  11. Other $200 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,393 74 payments
  2. Consulting Fee $2,250 1 payment
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $500 2 payments
Products named General payments · program years 2019–2025
  1. MENTOR MemoryGel Resterilizable Gel Sizer $1,479 24 payments
  2. Xeomin $628 10 payments
  3. SIENTRA HIGH STRENGTH COHESIVE SILICONE GEL BREAST IMPLANT $551 4 payments
  4. MemoryGel Breast Implants $365 7 payments
  5. ASCLERA $337 5 payments
  6. INTEGRA DERMAL REGENERATION TEMPLATE $230 2 payments
  7. PRIMATRIX $230 2 payments
  8. OviTex 2S $171 1 payment
  9. OviTex Reinforced Bioscaffold With Permanent Polymer (OviTex) $166 1 payment
  10. TITAN $143 1 payment
  11. Other $1,635 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medical Device Business Services, Inc. $2,341 2 payments
  2. Sientra, Inc. $1,750 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

278

Median for General Surgery: 59

Drug cost

$3,087

Median for General Surgery: $393

Branded share of claims

38.8%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cephalexin Generic 47 $583
Ondansetron Odt Ondansetron Brand 39 $575
Scopolamine Generic 25 $420
Valacyclovir Valacyclovir Hcl Brand 17 $414
Promethazine Hcl Generic 28 $373
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 52 $345
Dexamethasone Generic 38 $236
Esomeprazole Magnesium Generic 32 $141

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Records

80 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic and Reconstructive Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record